Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

INSM vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Captures Overall Composite Edge (40.3 SELL vs 39.6 SELL), While INSM Leads 4–2 on Growth & Valuation Pillars

MRNA Overall Winner 6-Pillar Tally: INSM 4 – 2 MRNA Matrix Metrics: INSM 3 – 7 MRNA

As of Nov 20, 2026, Moderna, Inc. (MRNA) captures the overall head-to-head institutional edge over Insmed, Inc. (INSM) on higher Unified Composite conviction (40.3/100 SELL vs. 39.6/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, R&D & Supply-Chain Moat), while INSM wins 4–2 across the 6-pillar growth and valuation breakdown. INSM trades at $141.33 (N/M Forward P/E, -41.7% operating margin) versus MRNA at $195.00 (23.0x Forward P/E, -80.8% operating margin).

  • Growth vs. Quality Trade-Off: MRNA earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. INSM 39.6/100 SELL) and 2.23β · 78% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both INSM (39.6/100 SELL) and MRNA (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INSM vs MRNA
INSM NASDAQ
Insmed, Inc.
Pharmaceutical Preparations
$141.33
-2.17% 1D
Market Cap $31.7B
TTM Revenue $1.52B
Forward P/E N/M
Beta / 30D Vol 0.37β · 91% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 73
RSI-14: 73.2 · SMA20: $115.11 · SMA50: $111.09
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89

6-Pillar Scorecard Institutional Category Breakdown (INSM 4 – 2 MRNA)

Columns: Metric · INSM · MRNA
1. Valuation Multiples MRNA
Forward P/E N/M 23.0x
Trailing P/E 106.4x 23.0x
PEG Ratio 1.09x N/M
EV / Revenue 21.0x 33.1x
2. Growth & Scale INSM
Revenue Growth (YoY) +268.4% +29.2%
Earnings Growth (YoY) +0.0% -85.1%
TTM Revenue (USD) $1.52B $2.52B
Market Cap $31.7B $80.7B
3. Profitability & Quality INSM
Gross Margin 84.4% -42.0%
Operating Margin -41.7% -80.8%
Net Profit Margin -39.9% -110.5%
Return on Equity (ROE) -72.5% -34.5%
4. Balance Sheet & Cash Flow INSM
Cash Generation (TTM) -$628M -$2.04B
Cash Flow Margin -41.3% -81.0%
Net Cash / Leverage $188M Net Debt (0.81x D/E) $3.03B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INSM
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 50.7% (37th %ile) 89.6% (52nd %ile)
Put/Call OI Skew 0.05x (Call-Skewed) 1.05x (Balanced)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity N/A 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INSM (3) vs MRNA (7)
Institutional Metric INSM MRNA Criterion Row Edge
Market Capitalization
Scale
$31.7B $80.7B Larger Scale MRNA
Trailing P/E Ratio
Valuation
106.4x 23.0x Lower Multiple MRNA
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+268.4% +29.2% Higher Growth INSM
Operating Margin (TTM)
Profitability
-41.7% -80.8% Higher Margin INSM
Net Profit Margin
Profitability
-39.9% -110.5% Higher Margin INSM
Return on Equity (ROE)
Capital Efficiency
-72.5% -34.5% Higher ROE MRNA
52-Week Range Position
Momentum
42% ($90–$213) 67% ($22–$281) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
0.37β · 91% Vol 2.23β · 78% Vol Lower Realized Risk MRNA
Unified Institutional Score
Composite Signal
39.6 / 100 (SELL) 40.3 / 100 (SELL) Higher Composite MRNA
Trailing 12M Revenue (USD)
Operating Scale
$1.52B $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
84.4% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.09x PEG · 21.0x EV/Rev N/M PEG · 33.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$628M ($188M Net Debt (0.81x D/E)) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INSM +52.44 pp
INSM: +48.67% · MRNA: -3.77%
3M Horizon MRNA +26.41 pp
INSM: +13.99% · MRNA: +40.4%
6M Horizon MRNA +282.93 pp
INSM: +33.03% · MRNA: +315.96%
1Y Horizon MRNA +737.02 pp
INSM: -30.57% · MRNA: +706.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period INSM Revenue MRNA Revenue INSM Op. Margin MRNA Op. Margin Margin Leader
FY2018 $10M $140M -3124.9% -306.0% MRNA
FY2019 $140M $60M -172.4% -906.8% INSM
FY2020 $160M $800M -161.3% -95.0% MRNA
FY2021 $190M $18.5B -199.0% 72.0% MRNA
FY2022 $250M $19.3B -186.4% 48.9% MRNA
FY2023 $310M $6.85B -232.5% -61.9% MRNA
FY2024 $360M $3.24B -241.5% -121.9% MRNA
FY2025 $610M $1.94B -205.6% -158.1% MRNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INSM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 50.7%
IV Percentile 37th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact INSM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $122.88 · IV 50.1%

INSM vs. MRNA: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of INSM ($12,288) vs. MRNA ($21,527) against risk-defined 5-day vertical and put-wall option structures.

INSM Spot $122.88 · IV 50.1%
INSM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $125 / $135 Bull Call Spread

Buy 1x $125C · Sell 1x $135C · 32d

Net Entry $360 Debit
T+5d @ +5% Move +$119 (+33%)
Max Risk / Buffer $360 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $110 / $100 Bull Put Spread

Sell 1x $110P · Buy 1x $100P · 60d

Net Entry $215 Credit
Max Credit / Yield +$215 (+27.4% RoM)
Max Risk / Buffer -12.2% Cushion ($785 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INSM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $31.7B market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ INSM vs MRNA Key Questions & Quantitative Answers

As of Nov 20, 2026, Moderna, Inc. (MRNA) captures the overall head-to-head institutional edge over Insmed, Inc. (INSM) on higher Unified Composite conviction (40.3/100 SELL vs. 39.6/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, R&D & Supply-Chain Moat), while INSM wins 4–2 across the 6-pillar growth and valuation breakdown. INSM trades at $141.33 (N/M Forward P/E, -41.7% operating margin) versus MRNA at $195.00 (23.0x Forward P/E, -80.8% operating margin). Growth vs. Quality Trade-Off: MRNA earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. INSM 39.6/100 SELL) and 2.23β · 78% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both INSM (39.6/100 SELL) and MRNA (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

INSM leads the Growth & Scale pillar: INSM posts +268.4% YoY revenue growth and +0.0% YoY earnings growth on $1.52B TTM revenue (84.4% gross margin, -41.7% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INSM cumulative revenue shifted +6000.0% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, INSM deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

MRNA screens cheaper on headline valuation multiples. INSM trades at N/M Forward P/E, 106.4x Trailing P/E, 1.09x PEG, and 21.0x EV/Revenue (-41.3% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INSM (-72.5% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, INSM carries 50.7% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.37β · 91% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.